Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 20,000 shares of Alkermes stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $19.76, for a total value of $395,200.00. Following the transaction, the senior vice president now owns 205,122 shares in the company, valued at $4,053,210.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ:ALKS traded up $0.41 on Friday, reaching $20.11. 1,980,200 shares of the company’s stock traded hands, compared to its average volume of 1,184,703. The company has a quick ratio of 2.42, a current ratio of 2.69 and a debt-to-equity ratio of 0.26. The stock has a 50-day simple moving average of $19.24 and a 200-day simple moving average of $22.38. The firm has a market cap of $3.17 billion, a PE ratio of -287.29 and a beta of 1.77. Alkermes Plc has a 12 month low of $17.11 and a 12 month high of $39.52.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.17. The business had revenue of $255.24 million for the quarter, compared to analysts’ expectations of $252.65 million. Alkermes had a negative return on equity of 6.08% and a negative net margin of 18.71%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $0.07 earnings per share. On average, equities analysts anticipate that Alkermes Plc will post -0.17 earnings per share for the current year.
ALKS has been the topic of several analyst reports. Piper Jaffray Companies lowered their target price on Alkermes from $30.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Goldman Sachs Group upgraded Alkermes from a “sell” rating to a “neutral” rating and set a $27.00 target price on the stock in a research report on Monday, July 15th. Stifel Nicolaus lowered their target price on Alkermes from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Wednesday, October 23rd. BidaskClub downgraded Alkermes from a “hold” rating to a “sell” rating in a research report on Friday, September 27th. Finally, HC Wainwright lowered their target price on Alkermes from $28.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. Alkermes currently has a consensus rating of “Hold” and a consensus target price of $27.27.
A number of large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its holdings in Alkermes by 3.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,275,957 shares of the company’s stock valued at $457,020,000 after acquiring an additional 697,027 shares during the period. Vanguard Group Inc. raised its holdings in Alkermes by 1.7% during the second quarter. Vanguard Group Inc. now owns 14,588,574 shares of the company’s stock valued at $328,828,000 after acquiring an additional 239,819 shares during the period. BlackRock Inc. raised its holdings in Alkermes by 10.4% during the second quarter. BlackRock Inc. now owns 11,137,923 shares of the company’s stock valued at $251,050,000 after acquiring an additional 1,052,841 shares during the period. Renaissance Technologies LLC raised its holdings in Alkermes by 139.7% during the second quarter. Renaissance Technologies LLC now owns 3,950,586 shares of the company’s stock valued at $89,046,000 after acquiring an additional 2,302,600 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Alkermes by 70.4% during the second quarter. AQR Capital Management LLC now owns 2,375,998 shares of the company’s stock valued at $53,080,000 after acquiring an additional 981,355 shares during the period. 95.70% of the stock is currently owned by institutional investors and hedge funds.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
See Also: Growth Stocks
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.